Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.

Pier Aldo Canessa, Maria Cristiana Franceschini, Paola Ferro, Enrico Battolla, Paolo Dessanti, Carmen Manta, Massimiliano Sivori, Riccardo Pezzi, Vincenzo Fontana, Franco Fedeli, Maria Pia Pistillo, Silvio Roncella

Research output: Contribution to journalArticle

Abstract

Soluble mesothelin-related peptide (SMRP) is regarded as an FDA approved biomarker for the diagnosis and monitoring of pleural malignant mesothelioma (MPM). We detected the SMRP levels in pleural effusions (PE) by means of an ELISA and analyzed their diagnostic relevance to differentiate MPM from benign pathology and from non-MPM pleural metastasis. Comparison with cytology in MPM-PE was also performed. We found that SMRP detection in MPM-PE can help the diagnosis of MPM and provide additional diagnostic value to cytology. We concluded that SMRP test may be incorporated into clinical practice of PE from patients suspicious for MPM.

Original languageEnglish
Pages (from-to)43-50
Number of pages8
JournalCancer Investigation
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 2013

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.'. Together they form a unique fingerprint.

  • Cite this

    Canessa, P. A., Franceschini, M. C., Ferro, P., Battolla, E., Dessanti, P., Manta, C., Sivori, M., Pezzi, R., Fontana, V., Fedeli, F., Pistillo, M. P., & Roncella, S. (2013). Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Investigation, 31(1), 43-50. https://doi.org/10.3109/07357907.2012.749265